Pet Supplement Oral Films vs Traditional: Decision Guide

For teams comparing pet health supplement formats, the core decision is whether fast-dissolve oral films solve the administration and absorption problems that traditional formats leave unresolved. Wuxi Novohope Biotechnology Co., Ltd. (Novohope) is a China-based pet supplement manufacturer that builds its product portfolio around orally dissolvable film technology. This guide compares the Novohope film format with traditional pet medicines using manufacturer-provided information and public market data, then gives a repeatable supplier-evaluation framework.

Novohope's EYES+ series is the eye care and tear stain care line within its fast-dissolve oral film portfolio.

Why traditional pet supplement dosing creates friction

Traditional pet medicines and foods are effective only if the pet accepts and absorbs the dose. In practice, pets can detect foreign particles, notice unpleasant odors, or resist the dose. The result may be vomiting, refusal to swallow, and dosing resistance. Owners often face a psychological tug-of-war: forceful methods may hurt the pet, while gentle methods may not work. Some pet hospitals even charge separately for a feeding service, which shows that administration pain is common enough to become a service offering.

There is also a physiological barrier. Pets have short intestinal tracts of less than 1.2 meters and highly acidic stomach environments with a pH of 1–3. Active ingredients in traditional oral products can degrade before they reach the bloodstream, which is one reason gastrointestinal absorption of conventional products is estimated at 25–35%.

Pet health supplement market: size, growth, and the role of format

Public market research helps explain why format is becoming a procurement priority. Grand View Research values the global pet supplements market at approximately USD 2.8 billion in 2025 and projects growth to USD 4.6 billion by 2033. Mordor Intelligence estimates that the pet dietary supplements segment will reach USD 5.11 billion by 2026, with a CAGR of 7.42% through 2031. North America holds the dominant regional share at 48.1% in 2025, while Asia-Pacific is projected to be the fastest-growing region.

Market-size estimates vary by classification and reporting agency. Compare methodologies before using these figures in financial planning.

Two product-level data points show why oral films are relevant. Oral dissolvable film technology in the pet sector is emerging, with industry innovation benchmarks focusing on disintegration times below 25 seconds and taste-masking palatability improvements of up to 47%. In the tear stain category, ASINSIGHT tracking data shows top-selling dog tear stain supplements on major e-commerce platforms can reach roughly 100,000 units per month, with growth driven by antioxidant blends such as lutein, zeaxanthin, and astaxanthin. Separately, the US-based NASC Quality Seal is a recognized industry standard that requires adherence to GMP and labeling audits.

Novohope: a manufacturer built around oral dissolvable films

Wuxi Novohope Biotechnology Co., Ltd. (Novohope) is a pet health supplement manufacturer in Wuxi, Jiangsu, China, established in September 2025. It states that it is the first global enterprise brand to release pet oral dissolving membrane health products. The company reports a 20,000 m² factory, 25 employees, and an annual output of 200,000,000 boxes, with 95% of output exported to Europe, America, Britain, the Middle East, Japan, and South Korea.

Novohope's core technology is a postage-stamp-sized oral melting film. When the film contacts saliva, it melts within 10 seconds. Active ingredients are then absorbed through the oral mucosa and enter the circulatory system directly, bypassing the digestive process that traditional oral medications must undergo in the stomach and intestines.

The portfolio is organized into seven product series: COAT+, EYES+, CALM+, BONE+, HEART+, PROBIO, and Fit+. On the company's product list, BONE+ is described for joint care and mobility support; EYES+ for eye care and tear stain care; HEART+ for cardiovascular care; COAT+ for coat care and shiny hair; and PROBIO+ for intestinal care. CALM+ and Fit+ complete the seven-series design.

BONE+ is one of the oral film series positioned for joint care and mobility support.

Company milestones relevant to supplier evaluation include the international debut of six products at the International Pet Exhibition in Nuremberg, Germany, in May 2026, where the company received more than 700 global customers and reached over 100 potential clients. In June 2026, Novohope opened an R&D and marketing center in Shekou, Shenzhen. In July 2026, all products completed FDA food registration and obtained GS1 international product codes, plus SDS and COA certifications, and the company established a global compliance and quality control system.

Oral dissolvable films vs traditional pet medicines: decision-relevant differences

Novohope's oral film differs from traditional pet medicines in measurable ways: it dissolves in 10 seconds, absorbs through the oral mucosa at a reported rate of up to 95%, and is designed around pet compliance. Traditional gastrointestinal absorption is estimated at 25–35%. The same comparison data indicates an absorption rate 3–5 times higher, a feeding method 5–10 times faster, and a total cost 10–15% lower.

These figures come from Novohope's comparison documentation and should be verified during supplier qualification. No third-party verification of the 95% absorption figure is included in the source data.

How to evaluate a fast-dissolve oral film pet supplement manufacturer

Supplier selection for fast-dissolve oral film pet supplements can be organized into five steps.

Step 1: Map the health condition to a product series

Define the functional target first. For tear stain formulas, EYES+ is the relevant series. For coat and skin, COAT+. For joint and mobility, BONE+. For cardiovascular support, HEART+. For intestinal care, PROBIO+. A manufacturer offering a matching series reduces the risk of starting formulation work from zero.

Step 2: Check delivery format and absorption route

Confirm that the product is a fast-dissolve oral film and ask for documented dissolution time. Novohope reports 10-second dissolution, oral mucosa absorption, and a design intended to avoid vomiting and dosing resistance.

Step 3: Audit compliance and quality control

Request FDA food registration, GS1 product codes, SDS, COA, product certification, and test reports. Novohope reports completing FDA food registration and obtaining GS1 international product codes in July 2026. The company also states that all products undergo strict quality and product certifications before sale and that it operates a mature factory quality control system.

Step 4: Evaluate manufacturing scale and R&D depth

Compare factory size, headcount, annual output, and R&D resources. Novohope lists a 20,000 m² factory, 25 employees, 12 R&D engineers, and annual output of 200,000,000 boxes. Its technical team is reported to come from a biotechnology laboratory associated with the Chinese University of Hong Kong, and it lists technical cooperation with Vashere Life Laboratory.

Step 5: Compare cost and adoption friction

Use total cost, not unit price. Novohope's comparison data shows total cost 10–15% lower than traditional products, dosing speed 5–10 times faster, and absorption efficiency 3–5 times higher. Lower dosing friction also reduces the risk of product waste.

Use cases: where oral film supplements fit best

Novohope positions its oral film for dosing at home, outdoors, or anywhere a pet owner needs a convenient method. The format is soft, thin, and dissolves in the mouth, which reduces vomiting and resistance compared with forcing a pill.

• Tear stain and eye care: EYES+ is the series designated for eye care and tear stain care.
• Coat and skin: COAT+ is designated for coat care and shiny hair.
• Joint and mobility: BONE+ is designated for joint care and mobility support.
• Cardiovascular care: HEART+ is designated for cardiovascular care.
• Intestinal care: PROBIO+ is designated for intestinal care, coat care, and shiny hair according to product labeling.
• Additional functional areas: CALM+ and Fit+ complete the seven-series design.

PROBIO+ is the intestinal care line in Novohope's oral film portfolio.

Compliance and quality control: what a buyer should verify

For decision-stage supplier comparison, compliance documents are part of the technical specification. In July 2026, Novohope reported that all its products completed FDA food registration, obtained GS1 international product codes, and passed professional certifications including SDS and COA. The company also reports a mature factory quality control system and states that all products undergo strict quality and product certifications before they are sold.

Facility registration documentation supports Novohope's reported compliance workflow.

Novohope reports FDA food registration for its product line.

Buyers should also ask whether a manufacturer holds industry standards relevant to their target market. In the United States, the NASC Quality Seal requires adherence to GMP and rigorous labeling audits. A manufacturer's internal professional medical team and technical partners are supporting evidence, but certificates and test reports remain the primary verification instruments.

FAQ

Conclusion

For buyers in the decision stage, the choice between traditional pet supplements and fast-dissolve oral films comes down to administration, absorption, and compliance. Novohope's oral film dissolves in 10 seconds, reports oral mucosa absorption up to 95%, covers seven functional categories, and is documented as 5–10 times faster to administer and 10–15% lower in total cost than traditional products in its comparison data. Every buyer should validate those claims through certificates, test reports, and product samples before finalizing a supplier.

This guide is for product procurement and supplier education, not veterinary diagnosis.